波士頓科學首款國產IVUS導管獲批，臨港本土智造賦能中國精準診療

上觀新聞

03/17

3月13日，波士頓科學宣佈，其一次性使用血管內超聲診斷導管OptiCross HD（以下簡稱「OptiCross HD」）正式獲得國家藥品監督管理局批准，將在上海臨港生產基地實現本土化生產。這也是波士頓科學在中國自有生產基地獲批的首個國產醫療器械產品，標誌着公司在中國高端介入診療領域邁出重要一步。　　作為波士頓科學本土化佈局的核心成果，OptiCross HD是國內獲批的首款60MHz高清血管內...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/news/2620478158"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620478158\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620478158?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-17 21:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620478158","market":"hk","top_or_hot":-1,"title":"波士頓科學首款國產IVUS導管獲批，臨港本土智造賦能中國精準診療","media":"上觀新聞","content":"<div>\n<p>3月13日，波士頓科學宣佈，其一次性使用血管內超聲診斷導管OptiCross HD（以下簡稱「OptiCross HD」）正式獲得國家藥品監督管理局批准，將在上海臨港生產基地實現本土化生產。這也是波士頓科學在中國自有生產基地獲批的首個國產醫療器械產品，標誌着公司在中國高端介入診療領域邁出重要一步。　　作為波士頓科學本土化佈局的核心成果，OptiCross HD是國內獲批的首款60MHz高清血管內...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603173674905459.html\">網頁鏈接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>波士頓科學首款國產IVUS導管獲批，臨港本土智造賦能中國精準診療</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n波士頓科學首款國產IVUS導管獲批，臨港本土智造賦能中國精準診療\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">上觀新聞</strong><span class=\"h-time small\">2026-03-17 21:48</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>3月13日，波士頓科學宣佈，其一次性使用血管內超聲診斷導管OptiCross HD（以下簡稱「OptiCross HD」）正式獲得國家藥品監督管理局批准，將在上海臨港生產基地實現本土化生產。這也是波士頓科學在中國自有生產基地獲批的首個國產醫療器械產品，標誌着公司在中國高端介入診療領域邁出重要一步。　　作為波士頓科學本土化佈局的核心成果，OptiCross HD是國內獲批的首款60MHz高清血管內...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603173674905459.html\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://finance.eastmoney.com/a/202603173674905459.html\">上觀新聞</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.SGD","symbol_name":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","start_time":0,"source_url":"http://finance.eastmoney.com/a/202603173674905459.html","article_id":"2620478158","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603173674905459.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620478158","pubTimestamp":1773755314,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"3月13日，波士頓科學宣佈，其一次性使用血管內超聲診斷導管OptiCrossHD（以下簡稱「OptiCrossHD」）正式獲得國家藥品監督管理局批准，將在上海臨港生產基地實現本土化生產。這也是波士頓科學在中國自有生產基地獲批的首個國產醫療器械產品，標誌着公司在中國高端介入診療領域邁出重要一步。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","BK4581":"高盛持仓","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BSX":"波士顿科学","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","BK4082":"医疗保健设备","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","BK4588":"碎股","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC"},"translate_title":"Boston Scientific's first domestic IVUS catheter was approved, and Lingang's local intelligent manufacturing empowers China's precision diagnosis and treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1.5},"content_text":"3月13日，波士頓科學宣佈，其一次性使用血管內超聲診斷導管OptiCross HD（以下簡稱「OptiCross HD」）正式獲得國家藥品監督管理局批准，將在上海臨港生產基地實現本土化生產。這也是波士頓科學在中國自有生產基地獲批的首個國產醫療器械產品，標誌着公司在中國高端介入診療領域邁出重要一步。　　作為波士頓科學本土化佈局的核心成果，OptiCross HD是國內獲批的首款60MHz高清血管內超聲導管，可與血管內超聲系統配合使用，在PCI手術中為醫生提供清晰的血管內部成像及精準測量數據，幫助醫生優化治療策略。未來將以臨港基地為支點，深化本土製造與創新，聯動臨床專家和本土夥伴，推動精準診療技術本土化迭代，惠及更多中國患者。　　中國心血管病患者眾多，隨着人口老齡化加劇，冠心病發病率上升，PCI手術量逐年增長，臨床對精準介入診療設備的需求日益迫切。血管內超聲（IVUS）被譽為冠脈介入醫生的「第三隻眼」，是冠脈檢查「金標準」，但目前其在國內PCI手術中的應用率遠低於發達國家，高端IVUS導管長期依賴進口，制約了臨床普及。　　OptiCross HD導管採用先進的複合換能器與寬頻技術，可清晰呈現血管三層結構及斑塊形態，增強支架結構可視化效果，助力醫生優化治療策略。其本土化生產填補了國產高端IVUS導管空白，將通過本土供應鏈提升供應效率，推動技術普及，為患者提供更可及的優質介入治療。　　OptiCross HD的本土化生產依託波士頓科學上海臨港基地，該基地是其在中國首個自有生產基地，也是臨港新片區生物醫藥產業高地的重要組成部分。臨港基地搭建了專用自動化生產線，以國際標準保障產品品質，依託自貿區優勢，本土生產的產品可直接供應全國，大幅縮短落地周期，快速響應臨床需求。　　此前，與OptiCross HD導管配合使用的血管內超聲系統已實現本土生產，此次OptiCross HD獲批投產，標誌着波士頓科學在中國正式實現血管內超聲領域「設備+導管」雙本土化佈局，打破高端介入診療設備及耗材依賴進口的格局，讓臨港基地逐步成為其全球供應鏈的「中國支點」，助力國內醫療器械產業升級。（文章來源：上觀新聞）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}